Phase 1b results show nintedanib DPI is safe and well tolerated in IPF patients, with no serious adverse events or discontinuations and only mild, transient cough. The ongoing Phase 2 trial will further assess safety, tolerability, and efficacy.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.